Thursday 22 May 2025
|
08.00-09.00 |
Registration |
|
|
08.45-09.00 |
Welcome Esvonc to Oporto |
|
|
|
Optimizing Cancer Therapy: Predictive Response, Dose Intensity, and Emerging Agents |
|
|
09.00-09.30 |
Prediction of drug response in human oncology based on genomics |
Dr. Fernanda Estevinho |
|
09.30-10.15 |
Drug dose and drug choice: Optimizing medical therapy for veterinary cancer: dosing schemes, novel combinations, and patient-specific dosing or selection of agents |
Dr. Dan Gustafson |
|
10.15-10.45 |
Coffee break |
|
|
10.45-11.15 |
Molecularly Targeted Agents in Veterinary Medicine: Optimal Use of New Drugs Becoming Available to Veterinary Oncology |
Dr. Dan Gustafson |
|
11.15-11.45 |
Revisiting Chemotherapy Dose Intensity and Antibiotic Prophylaxis in Veterinary Oncology: Clinical Impacts and old dogmas |
Jessica Lawrence |
|
11.45-12.15 |
Panel discussion |
Speaker Panel |
|
12.15-14.15 |
Lunch & Poster session |
|
|
14.15-14.45 |
Sponsored talk by IDEXX
IDEXX Cancer Dx™: What is it and what do I need to know? This educational session will focus on the innovation and impact of a new diagnostic tool for the early detection of lymphoma in canines, IDEXX Cancer Dx™. Attendees will learn the scientific foundation, clinical applications and how this diagnostic tool is revolutionizing veterinary practices by allowing broader access to cancer diagnostics. |
Clemence Peyron, DVM, DESV-Médecine Interne |
|
|
General abstracts |
|
| 15.00-15.12 |
Genetic Signatures of Therapeutic Response in Canine Cancers |
Dawn Duval |
| 15.12-15.24 |
Using evolutionary constraint to identify functional mutations in the non-coding space of canine osteosarcoma and diffuse large b-cell lymphoma. |
Maja Arendt |
| 15.24-15.36 | A novel screening platform for personalized molecular targeted therapy in veterinary oncology |
Namiko Ikeda |
| 15.36-15.48 |
Evaluation of whole-body diffusion-weighted imaging for the staging of canine multicentric lymphoma |
Laura Barrett |
| 15.48-16.00 |
A Novel Anti-CD20 mAb for Treatment of Canine B-cell Lymphoma: Pharmacokinetic and Safety Assessment |
Andi Flory |
|
16.00-16.30 |
Coffee break |
|
|
|
Residents abstracts |
|
| 16.30-16.42 |
Mediastinal lymphoma in 70 dogs treated with lomustine or anthracycline-based multi-agent chemotherapy: a multicenter retrospective study |
Diogo Machado |
| 16.42-16.54 |
Evaluation of a multidrug chemotherapy protocol including alkylating agents for treating canine high-grade T-cell lymphoma |
Hannah Versteegh |
| 16.54-17.06 |
Computed tomography features of salivary glands neoplasia in dogs |
Riccardo Finotello |
| 17.06-17.18 | Extracellular Vesicles from Canine Hemangiosarcoma Cell Lines as Potential Anti-Cancer Drug Delivery Systems |
Yasmine Dadi |
| 17.18-17.30 |
Preliminary Evaluation of Thalidomide as a Rescue Therapy for Canine Multiple Myeloma |
Stefano Ciccarelli |
|
17.30-18.00 |
ESVONC Clinical Research Fund Sponsored by
|
ESVONC CRF Committee |
|
19.00-21.00 |
Welcome Reception
|
|
